Overall Winner: Qure.ai·70/ 100

Qure.ai vs Regard AI

In-depth comparison — valuation, funding, investors, founders & more

Winner
Q
Qure.ai

🇮🇳 India · Prashant Warier

Series DAI HealthcareEst. 2016

Valuation

$270M

Total Funding

$157M

70
Awaira Score70/100

250 employees

Full Qure.ai Profile →
R
Regard AI

🇺🇸 United States

Series BAI HealthcareEst. 2017

Valuation

N/A

Total Funding

$30M

55
Awaira Score55/100

50-200 employees

Full Regard AI Profile →
🔬

Analyst Summary

Generated from real data · No AI hallucinations

Both Qure.ai and Regard AI compete directly in the AI Healthcare space, making this a head-to-head matchup within the same market segment. Qure. Regard AI builds an AI clinical documentation assistant that integrates with hospital electronic health record systems to automatically identify potential diagnoses, surface relevant clinical evidence from patient records, and generate structured documentation for physician review.

Qure.ai carries a known valuation of $270M, while Regard AI's valuation has not been publicly disclosed. On the funding side, Qure.ai has raised $157M in total — $127M more than Regard AI's $30M.

Qure.ai has 1 year more market experience, having been founded in 2016 compared to Regard AI's 2017 founding. In terms of growth stage, Qure.ai is at Series D while Regard AI is at Series B — a meaningful difference for investors evaluating risk and upside.

Qure.ai operates out of 🇮🇳 India while Regard AI is based in 🇺🇸 United States, giving each a distinct home-market advantage. On Awaira's 0–100 composite score, Qure.ai leads with a score of 70, reflecting stronger overall fundamentals across valuation, funding, and growth signals.

Metrics Comparison

MetricQure.aiRegard AI
💰Valuation
$270M
N/A
📈Total Funding
$157MWINS
$30M
📅Founded
2016
2017WINS
🚀Stage
Series D
Series B
👥Employees
250
50-200
🌍Country
India
United States
🏷️Category
AI Healthcare
AI Healthcare
Awaira Score
70WINS
55

Key Differences

📈

Funding gap: Qure.ai has raised $127M more ($157M vs $30M)

📅

Market experience: Qure.ai has 1 year more (founded 2016 vs 2017)

🚀

Growth stage: Qure.ai is at Series D vs Regard AI at Series B

👥

Team size: Qure.ai has 250 employees vs Regard AI's 50-200

🌍

Market base: 🇮🇳 Qure.ai (India) vs 🇺🇸 Regard AI (United States)

⚔️

Direct competitors: Both operate in the AI Healthcare market segment

Awaira Score: Qure.ai scores 70/100 vs Regard AI's 55/100

Which Should You Choose?

Use these signals to make the right call

Q

Choose Qure.ai if…

Top Pick
  • Higher Awaira Score — 70/100 vs 55/100
  • More established by valuation ($270M)
  • Stronger investor backing — raised $157M
  • More market experience — founded in 2016
  • India-based for regional compliance or proximity
  • Qure
R

Choose Regard AI if…

  • United States-based for regional compliance or proximity
  • Regard AI builds an AI clinical documentation assistant that integrates with hospital electronic health record systems to automatically identify potential diagnoses, surface relevant clinical evidence from patient records, and generate structured documentation for physician review

Funding History

Qure.ai raised $157M across 5 rounds. Regard AI raised $30M across 0 rounds.

Qure.ai

Series D

Jan 2021

$81M

Series C

Jan 2020

$50M

Series B

Jan 2018

$20M

Series A

Jan 2017

Lead: Accel Partners

$6M

Seed

Jan 2016

Regard AI

No public funding data available.

Investor Comparison

No shared investors detected between these two companies.

Unique to Qure.ai

Accel PartnersBessemer Venture PartnersGoogle

Users Also Compare

FAQ — Qure.ai vs Regard AI

Is Qure.ai bigger than Regard AI?
Qure.ai has a disclosed valuation of $270M, while Regard AI's valuation is not publicly available, making a direct size comparison difficult. Qure.ai employs 250 people.
Which company raised more funding — Qure.ai or Regard AI?
Qure.ai has raised more in total funding at $157M, compared to Regard AI's $30M — a gap of $127M. Combined, the two companies have completed 5 known funding rounds.
Which company has a higher Awaira Score?
Qure.ai holds the higher Awaira Score at 70/100, compared to Regard AI's 55/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 15-point gap that reflects meaningful differences in scale or traction.
Who founded Qure.ai vs Regard AI?
Qure.ai was founded by Prashant Warier in 2016. Regard AI's founder information is not currently available in our database.
What does Qure.ai do vs Regard AI?
Qure.ai: Qure.ai is an Indian artificial intelligence company founded in 2016 that develops machine learning solutions for diagnostic imaging in healthcare. The company specializes in computer-aided detection and diagnosis systems that analyze medical imaging data including chest X-rays, CT scans, and mammograms to identify abnormalities and assist radiologists in clinical decision-making. Its platform uses deep learning algorithms trained on large datasets to detect conditions such as tuberculosis, COVID-19, lung cancer, and other pathologies. Qure.ai's products are deployed across hospitals and diagnostic centers in India and internationally, serving both institutional healthcare providers and diagnostic chains. The company has secured $157 million in total funding and operates at Series D stage with a valuation of $300 million as of recent rounds. Its technology addresses the shortage of radiologists in developing markets while improving diagnostic accuracy and turnaround times. Qure.ai competes in the medical AI space alongside companies like IBM Watson Health, Zebra Medical Vision, and various regional diagnostic AI providers. The company has demonstrated strong traction in the Indian healthcare market and has expanded its reach to international markets. Its growth trajectory reflects increasing adoption of AI-assisted diagnostic solutions globally and the rising demand for scalable healthcare technologies in resource-constrained settings. Qure.ai focuses specifically on diagnostic imaging AI for markets with radiologist shortages, positioning it distinctly within underserved geographies. Regard AI: Regard AI builds an AI clinical documentation assistant that integrates with hospital electronic health record systems to automatically identify potential diagnoses, surface relevant clinical evidence from patient records, and generate structured documentation for physician review. The system is designed to reduce the documentation burden on hospitalists and clinical teams while improving diagnostic completeness and coding accuracy.\n\nThe company raised approximately 30 million USD and has deployed across hospital systems focused on reducing physician administrative load, a problem that contributes to clinician burnout and documentation errors with downstream billing and quality implications. Regard operates as a background analysis layer that surfaces findings without requiring clinicians to change their existing EHR workflow.\n\nClinical documentation AI sits at the intersection of physician workflow optimization and revenue cycle management, giving it a dual value proposition that justifies enterprise procurement from both clinical operations and hospital finance departments. Regard competes with Nuance DAX, Abridge, and other ambient documentation tools, but its focus on diagnostic suggestion and coding completeness rather than pure transcription differentiates its clinical and financial value story.
Which company was founded first?
Qure.ai was founded first in 2016, giving it 1 year of additional market experience. Regard AI was founded later in 2017. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.
Which company has more employees?
Qure.ai has approximately 250 employees, while Regard AI has approximately 50-200. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.
Are Qure.ai and Regard AI competitors?
Yes, Qure.ai and Regard AI are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.